However, preliminary DL1-DL4 pharmacokinetic data showed a trend for a negative correlation between LPT dose and VNR clearance (see below), warranting the exploration of an immediate higher and approved LPT dose with the VNR dose used in DL3 in order to confirm potential pharmacokinetic interactions and to decide whether full dose anti-HER2 therapy could be maintained in the final combination.
← all excerpts
Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.
2
—
—
The sentences
It decreased inversely according to LPT doses, although this decrease did not reach statistical significance ( Figure 2 ).